orlistat
orlistat.JPG

CLINICAL USE

Adjunct in obesity

DOSE IN NORMAL RENAL FUNCTION

120 mg taken immediately before, during or up to 1 hour after each meal; maximum 360 mg daily

PHARMACOKINETICS

  • Molecular weight                           :495.7
  • %Protein binding                           :>99
  • %Excreted unchanged in urine     : 0–4
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :1–2/unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAcarbose: avoid concomitant administration
  • Anticoagulants: monitor INR more frequently
  • Ciclosporin: possibly reduces absorption of ciclosporinVitamins: may reduce the absorption of fat soluble vitamins

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    If the meal doesn’t contain any fat, omit orlistatOrlistat is poorly absorbed; bioavailability of less than 5%.



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs